Presenters
Course Details
Hypertension is a major risk factor in the development of macrovascular diseases, such as heart attack and stroke. In this episode of Hypertension Weekly Practice Webisodes of the Philippine Society of Hypertension, Dr. Jhoanna G. Marcelo (Philippine Heart Center) talked about the mechanisms involved in the pathogenesis of macrovascular disease and the principles of blood pressure control to prevent macrovascular disease. Dr. Helenne Joie M. Brown (Saint Louis University School of Medicine) then discussed the clinical evidence supporting the use of RAS blockade in the management of hypertension with macrovascular disease and the benefits of telmisartan in high cardiovascular risk patients.
About the speakers
Dr. Jhoanna G. Marcelo is a Specialist in Internal Medicine, Adult Cardiology, and Coronary and Structural Interventional Cardiology at the Philippine Heart Center. She is also a Council Member of the Council on Cardiac Catheterization of the Philippine Heart Association.
Dr. Helenne Joie M. Brown is an Associate Professor of Saint Louis University (SLU) School of Medicine. She is the Chair of the Department of Internal Medicine of SLU Hospital of the Sacred Heart, and is a Past President of the Philippine Heart Association, Baguio-Benguet Chapter.
Estimated time of Completion: 1 hr. 23 mins. 45 secs.
CPD Points: 1 Point
PRC Program No: PROG-2022-41984
PSH Webisode Series: Hypertension and Macrovascular Disease Course Outline
Jhoanna G. Marcelo, MD, FPCP, FPCC – Hypertension and Macrovascular Disease
- What are macrovascular diseases
- Risk of Macrovascular diseases in Hypertension
- Why do macrovascular diseases occur
- Crossroads – microvascular and macrovascular disease
- Treatment goals
Helenne Joie M. Brown, MD, FPCP, FPCC, FPSCCI – ARBs in the Management of Hypertension in Patients with Macrovascular Disease
- Prevalence of Hypertension
- 2020 ISH Simplified Classification of Hypertension Risk
- Initiation of Treatment
- 2020 Philippine Hypertension CPG
- High Risk Patients: Advantage of RAAS inhibitors
- Heart Outcomes Prevention Evaluation (HOPE) Study
- Meta-analysis of antihypertensive agents in patients with established CVD
- Telmisartan in the prevention of CV events in high-risk patients (e.g., with macrovascular disease)
- Pharmacological Profile of Telmisartan
- The Trough/Peak Ratio
- All Receptor Antagonists: Comparative Pharmacokinetic Profile
- Telmisartan’s Long Duration of Effect BP Reduction After Active Dose vs Valsartan
- Changes in coronary plaque (IB-IVUS) in telmisartan-treated patients
- Coronary sinus cytokine levels in telmisartan-treated patients
- Endothelial dysfunction after coronary DES in telmisartan-treated hypertensive patients
- ONTARGET
- Telmisartan is As Effective as Ramipril in Preventing CV Events at Increased CV Risk
- Summary
PC-PH-103170 / September 2023